Skip to main content
SpringerLink
Log in

The Drug Discovery Process: How Do New Glaucoma Medications Come to Market?

  • Chapter
  • First Online:
The Glaucoma Book

  • 2595 Accesses

Abstract

In the United States of America, no drugs have been approved to treat glaucoma in the past 25 years. The vast majority of drugs in the glaucoma specialist’s armamentarium are indicated for the reduction (or treatment) of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension - or words to that effect. Internationally, the situation is quite different, but this review will focus primarily on how drugs (and more specifically, glaucoma drugs) are discovered and developed for the US market.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 219.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 279.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Maren TH, Mayer E, Wadsworth BC. Carbonic anhydrase inhibition. I. The pharmacology of Diamox, 2-acetylamino-1,3,4,-thiadizole 5-sulfonamide. Bull Johns Hopkins Hosp. 1954;95:199–243.

    CAS  PubMed  Google Scholar 

  2. Becker B. Diamox and the therapy of glaucoma. Am J Ophthalmol. 1954;38:16–17.

    Google Scholar 

  3. Ponticello GS, Sugrue MF, Plazonnet B, et al. Dorzolamide, a 40-year wait: from an oral to a topical carbonic anhydrase inhibitor for the treatment of glaucoma. In: Borchardt RT, Freidinger RM, Sawyer TK, Smith PL, eds. Integration of Pharmaceutical Discovery and Development. New York, NY: Plenum; 1998:555–574.

    Google Scholar 

  4. Camras CB, Bito LZ, Eakins KE. Reduction of intraocular pressure by prostaglandins applied topically to the rabbit eye. Invest Ophthalmol Vis Sci. 1977;16:1125–1134.

    CAS  PubMed  Google Scholar 

  5. Camras CB, Bito LZ. Reduction of intraocular pressure in normal and glaucomatous primate (Aotus trivirgatus) eyes by topically applied PGF2a. Curr Eye Res. 1981;1:205–209.

    Article  CAS  PubMed  Google Scholar 

  6. Bito LZ. A new approach to the medical management of glaucoma, from the bench to the clinic and beyond. Invest Ophthalmol Vis Sci. 2001;42:1126–1133.

    CAS  PubMed  Google Scholar 

  7. Giuffrè G. The effects of prostaglandin F2a in the human eye. Graefes Arch Clin Exp Ophthalmol. 1985;222:139–141.

    Article  PubMed  Google Scholar 

  8. Stjernschantz JW. From PGF2a-isopropyl-ester to latanoprost: a review of the development of Xalatan. Invest Ophthalmol Vis Sci. 2001;42:1134–1145.

    CAS  PubMed  Google Scholar 

  9. Villumsen J, Alm A, Söderström M. Prostaglandin F2 alpha-isopropylester eye drops: effect on intraocular pressure in open-angle glaucoma. Br J Ophthalmol. 1989;73(12):975–979.

    Article  CAS  PubMed  Google Scholar 

  10. Hellberg MR, Sallee VL, McLaughlin MA, et al. Preclinical efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist. J Ocul Pharmacol Ther. 2001;17:421–432.

    Article  CAS  PubMed  Google Scholar 

  11. Hellberg MR, McLaughlin MA, Sharif NA, et al. Identification and characterization of the ocular hypotensive efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist, and AL-6598, a DP prostaglandin receptor agonist. Surv Ophthalmol. 2002;47(Suppl 1):S13-S33.

    Article  PubMed  Google Scholar 

  12. Gordon MO, Beiser JA, Brandt JD, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:714–720.

    PubMed  Google Scholar 

  13. Leske MC, Heijl A, Hussein M, et al. Factors for glaucoma progression and the effect of treatment: the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2003;121:48–56.

    PubMed  Google Scholar 

  14. Chauhan BC, Mikelberg FS, Balaszi AG. Canadian Glaucoma Study 2. Risk factors for the progression of open-angle glaucoma. Arch Ophthalmol. 2008;126(8):1030–1036.

    Article  PubMed  Google Scholar 

  15. Spilker B. Multinational Pharmaceutical Companies: Principles and Practices. 2nd ed. New York, NY: Raven; 1994.

    Google Scholar 

  16. Ng R. Drugs from Discovery to Approval. Hoboken, NJ: John; 2004.

    Google Scholar 

  17. Campbell JJ. Understanding Pharma - A Primer on How Pharmaceutical Companies Really Work. Raleigh, NC: Pharmaceutical Institute; 2005.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacology and Neuroscience, University of North Texas Health Services Center, Fort Worth, TX, USA

    Michael Bergamini BS, PhD

Authors
  1. Michael Bergamini BS, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. 2889 10th Avenue, N., Palm Springs, 33461, USA

    Paul N. Schacknow

  2. Casey Eye Institute, Dept. Ophthalmology, Oregon Health & Sciences University, SW. Terwilliger Blvd. 3375, Portland, 97201-4197, USA

    John R. Samples

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Bergamini, M. (2010). The Drug Discovery Process: How Do New Glaucoma Medications Come to Market?. In: Schacknow, P., Samples, J. (eds) The Glaucoma Book. Springer, New York, NY. https://doi.org/10.1007/978-0-387-76700-0_86

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-76700-0_86

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-76699-7

  • Online ISBN: 978-0-387-76700-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation